Foundation for Sickle Cell Disease Research Receives 200 Doses of the COVID-19 Moderna Vaccine For Its Patient Population

HOLLYWOOD, Fl.  —The Foundation for Sickle Cell Disease Research, LLC (FSCDR), which is a stand-alone, community-based medical and research practice, recently received 200 doses of the COVID-19 Moderna Vaccine for its patient population.

Sickle Cell On March 22, 2021, FSCDR began administering the vaccines to any individuals with sickle cell disease/sickle cell trait. Those who would like to receive the vaccine must reside in the state of Florida, and they do not have to be a patient at FSCDR. FSCDR’s flagship location where the vaccines will be administered is located at 1685 S. State Road 7, Unit 4, Hollywood, Florida 33023.

“We are elated to be able to provide vaccinations to individuals with sickle cell disease/sickle cell trait. This is truly a momentous achievement since the vaccine will give much-needed hope to these individuals. As the first step to stopping the spread of this pandemic, we have thoroughly prepared to administer the vaccines at our flagship location,” said Lanetta Bronté-Hall, MD, MPH, MSPH, President and Chief Health Officer. “Our entire team is hopeful for the future. Not only are we optimistic that the vaccine will bring some type of normality, but we are also hopeful that the vaccine will help reduce the burden for individuals with sickle cell disease/sickle cell trait.”

As stated, the supply for the initial rollout is 200 total doses. As more supply becomes available, FSCDR will continue to offer vaccinations. 

For individuals with sickle cell disease and sickle cell trait, FSCDR has asked them to fill out the form at this link prior to receiving their vaccine: